July 31, 2017 07:21 AM EDT
Pharma

Loxo beefs up its ge­net­ics-based can­cer drug pipeline with an un­usu­al $40M deal

John Carroll

Editor & Founder

Af­ter build­ing on its rep as a ge­net­i­cal­ly-fo­cused can­cer drug com­pa­ny at AS­CO with the lat­est up­date on larotrec­tinib (LOXO-101), Loxo On­col­o­gy is now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

A service from the Financial Times